欢迎来到艾兰博曼,请 登录 | 立即注册
查看: 1238|回复: 3

【资讯翻译】Chronic Symptoms After HPV Vaccine: Part of Wider Syndrome?

[复制链接]

0

听众

0

收听

355

积分

版主

Rank: 7Rank: 7Rank: 7

积分
355
发表于 2016-8-12 10:29:50 | 显示全部楼层 |阅读模式
IAVI Awarded NIH Contract to Expedite AIDS Vaccine Development

The International AIDS Vaccine Initiative (IAVI) has been awarded a new contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH) to expedite the development of promising AIDS vaccine candidates.

Under the contract, IAVI will provide a range of product development services to advance the characterization and manufacturing of HIV envelope protein immunogens designed by NIAID-supported scientists. The agreement provides for funding in an amount up to US$98M over a seven-year period.

HIV envelope protein immunogens are being developed in an effort to induce a broad and effective protective immune response to help prevent HIV infection. Manufacturing of these immunogens so that they can be evaluated in human clinical trials has proved challenging given the complexity and instability of the HIV envelope proteins. Translating promising research concepts from the laboratory into vaccine candidates that can be evaluated for safety and the ability to elicit targeted immune responses in human clinical studies represents a major obstacle facing many researchers working on envelope immunogens globally. Optimizing HIV vaccine manufacturing processes should help expedite the development and evaluation of promising vaccine candidates across the entire field.

“We are very pleased to expand the provision of vaccine product development expertise to support NIAID-sponsored AIDS vaccine programs,” IAVI President and CEO Mark Feinberg said. “NIAID is the largest funder of HIV vaccine research worldwide, and IAVI welcomes the opportunity to work with them to help advance their efforts and those of the numerous outstanding researchers they support. IAVI is dedicated to expediting the development and global availability of an effective HIV vaccine, and is committed to supporting the success of the overall efforts of the HIV vaccine field. Building on IAVI’s experience in the characterization and production of HIV envelope vaccine candidates, our efforts to advance the work of NIAID-supported investigators will also provide additional opportunities to develop and share insights and innovations into how to make the HIV vaccine production process as reliable, robust and timely as possible. Given the imperative to accelerate HIV vaccine development efforts, this new partnership with NIAID promises to facilitate meaningful progress and impact towards this goal.”

IAVI and NIAID have been partnering closely in AIDS vaccine research for many years, including in the design and development of HIV envelope immunogens to elicit broadly protective antibody responses.

http://www.medicalnewsservice.com/iavi-awarded-nih-contract-expedite-aids-vaccine-development/



0

听众

1

收听

47

积分

新手上路

Rank: 1

积分
47
发表于 2016-8-12 13:09:50 | 显示全部楼层
这篇我领了

0

听众

1

收听

47

积分

新手上路

Rank: 1

积分
47
发表于 2016-8-13 00:34:09 | 显示全部楼层
国际艾滋病疫苗行动组织与美国国立卫生研究院签订合约,进一步加快艾滋病疫苗的研发

国际艾滋病疫苗行动组织(IAVI)与美国国立研究院(NIH)的下属部门,即美国国立变态反应与感染病研究所(NIAID)签订合约,进一步推动其研发出令人期待的抗艾滋病疫苗候选物

根据合约,NIH将会拨给IAVI总额高达9800万美金的基金。在七年的合同期内,对于NIAID科学家设计的HIV包膜蛋白抗原,IAVI则要设法将这种抗原研制出来,同时要不断改善其特性。

HIV包膜蛋白抗原的研制,有望于在防治HIV感染过程中产生广泛而有效的免疫保护效应。它可能推动HIV人体试验进入极具挑战性的阶段,帮助评估HIV包膜蛋白的复杂性以及不稳定性。从先进的实验室研究理念,到HIV疫苗候选物的研制成功,再到人体试验的开展,通过受试者的免疫应答反应来评估其安全性与稳定性。这在全球HIV包膜蛋白抗原研究中,都是众多研究者所要攻克的首要难关。寻找到最佳的HIV疫苗研制方法,在整个领域范围内,都将有力推动令人期待的HIV疫苗候选物的研发以及后期评估。

“为了更好地支持NIAID赞助的艾滋病疫苗研发项目,我们将欣然扩大对HIV疫苗产品的研发投入。“”IAVI总裁兼首席执行官Mark Feinberg 讲道,“NIAID是世界范围内HIV疫苗研究的最大投资者,IAVI很珍惜与之合作的机会,愿与其众多杰出研究者一起,共同努力。IAVI一直致力于尽快研发出一种全球通用的有效HIV疫苗,对现有HIV疫苗研究领域内取得的成果也提供了大力支持。得益于AIVI已有的关于HIV包膜蛋白候选物的研发与特性认知经验,我们将会稳健及时地推动NIAID研究者们的工作,在HIV疫苗制造法方面,我们也会进一步提高洞察力与创新意识,并与大家及时分享。考虑到推进HIV疫苗研发工作的必要性,AIVI和NIAID建立新型合作关系,在以后的HIV疫苗研制工作上将会取得更重要的进步,发挥更重要的作用。“

在艾滋病疫苗研究上,IAVI与NIAID原就保有多年的合作关系,包括HIV包膜蛋白的设计与研发,共同致力于产生广泛性的免疫保护效应。

0

听众

0

收听

355

积分

版主

Rank: 7Rank: 7Rank: 7

积分
355
 楼主| 发表于 2016-8-15 09:46:36 | 显示全部楼层
收了
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

© 2013 艾兰博曼 All Rights Reserved.
( 浙ICP备07020270号-8 )
 
快速回复 返回顶部 返回列表